WHO ICTRP trial
An open-label, phase 1b study to evaluate the safety, tolerability…
ACTRN12622000927729 · Australian New Zealand Clinical Trials Registry (ANZCTR) · Not Recruiting
Key facts
| Trial ID | ACTRN12622000927729 |
|---|---|
| Public title | An open-label, phase 1b study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of a single dose of PMX205 in patients with amyotrophic lateral sclerosis |
| Scientific title | An open-label, phase 1b study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of two doses of PMX205 in patients with amyotrophic lateral sclerosis |
| Primary sponsor | Alsonex Pty Ltd |
| Registry | Australian New Zealand Clinical Trials Registry (ANZCTR) |
| Recruitment status | Not Recruiting |
| Study type | Interventional |
| Phase | Phase 1 |
| Countries | Australia |
| Conditions | Amyotrophic Lateral Sclerosis;Motor Neuron Disease;Parkinson's Disease; Amyotrophic Lateral Sclerosis Motor Neuron Disease Parkinson's Disease;Neurological - Neurodegenerative diseases;Inflammatory and Immune System - Other inflammatory or… |
| Interventions | The intervention to be administered is PMX205, a non approved experimental therapy which inhibits the complement cascade. The doses administered are 0.4 mg/kg and 0.8 mg/kg of PMX205 by a single injection and will be administered on one… |
| Registration date | Jun 29, 2022 |
| Target size | 8 |
| Registry page | anzctr.org.au |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: